Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial1
- 1 August 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Acta Pharmacologica Sinica
- Vol. 26 (8), 926-933
- https://doi.org/10.1111/j.1745-7254.2005.00150.x
Abstract
APS (Acta Pharmacologica Sinica), the top pharmacology research journal based in China, publishes original articles and reviews on all aspects of pharmacology and the related life sciencesKeywords
This publication has 35 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialThe New England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionThe New England Journal of Medicine, 2005
- COX-3 and the mechanism of action of paracetamol/acetaminophenProstaglandins, Leukotrienes & Essential Fatty Acids, 2005
- Cellular distribution and contribution of cyclooxygenase (COX)-2 to diabetogenesis in NOD mouseCell and tissue research, 2002
- Susceptibility of Cyclooxygenase-2-Deficient Mice to Pulmonary FibrogenesisThe American Journal of Pathology, 2002
- Expression of cyclooxygenase‐2 in intestinal goblet cells of pre‐diabetic NOD miceActa Physiologica Scandinavica, 2002
- Cyclooxygenase-2 Expression in Lipopolysaccharide-Stimulated Human Monocytes Is Modulated by Cyclic AMP, Prostaglandin E2, and Nonsteroidal Anti-inflammatory DrugsBiochemical and Biophysical Research Communications, 2000
- Macula densa signalling—a potential role of cyclooxygenase‐2 (COX‐2)?Nephrology Dialysis Transplantation, 2000
- Ursolic Acid from Plantago major, a Selective Inhibitor of Cyclooxygenase-2 Catalyzed Prostaglandin BiosynthesisJournal of Natural Products, 1998
- Correction: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agentsNature, 1997